Macrophage membrane coated and loaded TRAF7 nanoparticles and application thereof in non-alcoholic fatty liver disease
Through the macrophage membrane-coated nanoparticles loaded with TRAF7, the existing drugs for the treatment of non-alcoholic fatty liver disease have been solved, and efficient targeting and genetic intervention in the lesion site has been achieved, effectively inhibiting the progress of the disease and having good biosafety.
Patent Information
- Application Number
- CN202411895447.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-22
- Publication Date
- 2025-03-25
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing drugs used to treat non-alcoholic fatty liver disease have limited efficacy and have great side effects. They have not been approved by the U.S. Food and Drug Administration, and it is urgent to develop effective therapeutic drugs.
The nanoparticles coated with TRAF7-loaded nanoparticles coated with macrophage membrane were prepared by the polylactic acid-glycolic acid copolymer PLGA as a nanocarrier and the TRAF7-shRNA plasmid with a specific promoter, and the nanoparticles coated with the macrophage membrane were prepared to obtain the nanoparticles coated by macrophage membrane.
The efficient targeting of PLGA-shTRAF7 and MM/PLGA-shTRAF7 in non-alcoholic fatty liver lesions was achieved, which enhanced the gene intervention effect, effectively inhibited the progress of non-alcoholic fatty liver disease, and had good biosafety.